Granulovirus – Talk Bio

Actionable Insights Powered by AI

Kathy High Takes Helm at GV, ARCH-Backed Eye Disease Biotech RhyGaze; Arvinas Sees Leadership Shift

3 months ago talkbio0Tagged Arch of foot, Arvinas, Changing, Granulovirus, GV, Kathy, Leadership, RhyGaze

Kathy High, RhyGaze, GV, ARCH, eye disease biotech, Arvinas, leadership changes

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

9 months ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures